최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생물정신의학 = Korean journal of biological psychiatry, v.19 no.4, 2012년, pp.187 - 192
김세현 (서울대학교 의학연구원 인간행동의학연구소) , 유현숙 (서울대학교병원 의생명연구원) , 박소영 (서울대학교병원 의생명연구원) , 김민경 (서울대학교 의과대학 의과학과) , 박홍근 (서울대학교병원 의생명연구원) , 김용식 (동국대학교 의과대학 일산병원 정신건강의학과)
Objectives Although antipsychotic drug clozapine has superior efficacy, this is hampered by metabolic side effects such as weight gain and diabetes. Recent studies demonstrate that clozapine induces insulin resistance. However, the identity and location of insulin resistance induced by clozapine has...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
비정형 항정신병약물의 장점은 무엇인가? | 비정형 항정신병약물은 기존의 정형 항정신병약물과 비교하여 추체외로 증상과 지연성 운동장애를 포함한 운동 부작용을 적게 유발하고, 음성 증상, 인지장애, 기분 증상 등에 치료 효과를 보이는 등 장점을 지니고 있다. 그러나 비정형 항정신병약물은 체중 증가, 지질 및 당 조절 이상과 같은 대사 부작용을 유발하며, 이는 장기 유지 치료의 큰 장애물로 작용한다. | |
항정신병약물에 의해 유발되는 당뇨병의 원인기전은 무엇이라고 추청하는가? | 그러나 비정형 항정신병약물에 의해 유발되는 당뇨병의 원인기전은 아직 잘 알려져 있지 않다. 비정형 항정신병약물은 인슐린 분비 저하보다는 인슐린 저항성 유발을 통해 당뇨병을 유발하는 것으로 생각되고 있다.3)6) 세로토닌, 노르아드레날린 수용체 등에 대한 작용이 인슐린 저항성을 유발하는 것으로 보고 되기도 하였으며,7) 약물 치료에 따른 체중 증가 및 복부 비만이 이차적으로 인슐린 저항성을 유발하는 것으로 생각되기도 하였다. | |
비정형 항정신병약물의 단점은 무엇인가? | 비정형 항정신병약물은 기존의 정형 항정신병약물과 비교하여 추체외로 증상과 지연성 운동장애를 포함한 운동 부작용을 적게 유발하고, 음성 증상, 인지장애, 기분 증상 등에 치료 효과를 보이는 등 장점을 지니고 있다. 그러나 비정형 항정신병약물은 체중 증가, 지질 및 당 조절 이상과 같은 대사 부작용을 유발하며, 이는 장기 유지 치료의 큰 장애물로 작용한다.1) 대사 부작용의 하나로서 비정형 항정신병약물은 제2형 당뇨병 발병의 위험을 증가시킨다. |
Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981.
Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006;67:789-797.
Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-1121.
Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566.
Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on wholebody insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289-297.
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35.
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, et al. Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. J Psychiatr Res 2010;44:493-498.
Hou JC, Pessin JE. Ins (endocytosis) and outs (exocytosis) of GLUT4 trafficking. Curr Opin Cell Biol 2007;19:466-473.
Ardizzone TD, Bradley RJ, Freeman AM 3rd, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 2001;923:82-90.
Panariello F, Perruolo G, Cassese A, Giacco F, Botta G, Barbagallo AP, et al. Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance. J Cell Physiol 2012;227:1485-1492.
Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:69-80.
Hill JW, Elmquist JK, Elias CF. Hypothalamic pathways linking energy balance and reproduction. Am J Physiol Endocrinol Metab 2008;294:E827-E832.
Levin BE, Magnan C, Dunn-Meynell A, Le Foll C. Metabolic sensing and the brain: who, what, where, and how? Endocrinology 2011;152:2552-2557.
Routh VH. Glucose sensing neurons in the ventromedial hypothalamus. Sensors (Basel) 2010;10:9002-9025.
Tulipano G, Rizzetti C, Bianchi I, Fanzani A, Spano P, Cocchi D. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 2007;85:61-70.
Martins PJ, Haas M, Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 2010;59:2418-2425.
Garcia-San Frutos M, Fernandez-Agullo T, De Solis AJ, Andres A, Arribas C, Carrascosa JM, et al. Impaired central insulin response in aged Wistar rats: role of adiposity. Endocrinology 2007;148:5238-5247.
Kim SH, Yu HS, Park HG, Jeon WJ, Song JY, Kang UG, et al. Dose-dependent effect of intracerebroventricular injection of ouabain on the phosphorylation of the MEK1/2-ERK1/2-p90RSK pathway in the rat brain related to locomotor activity. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1637-1642.
Yu HS, Kim SH, Park HG, Kim YS, Ahn YM. Intracerebroventricular administration of ouabain, a Na/K-ATPase inhibitor, activates tyrosine hydroxylase through extracellular signal-regulated kinase in rat striatum. Neurochem Int 2011;59:779-786.
Niswender KD, Morrison CD, Clegg DJ, Olson R, Baskin DG, Myers MG Jr, et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes 2003;52:227-231.
Gerozissis K. Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol 2008;585:38-49.
Kalra SP. Pivotal role of leptin-hypothalamus signaling in the etiology of diabetes uncovered by gene therapy: a new therapeutic intervention? Gene Ther 2011;18:319-325.
Prodi E, Obici S. Minireview: the brain as a molecular target for diabetic therapy. Endocrinology 2006;147:2664-2669.
Sanchez-Lasheras C, Konner AC, Bruning JC. Integrative neurobiology of energy homeostasis-neurocircuits, signals and mediators. Front Neuroendocrinol 2010;31:14-15.
Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001;25 Suppl 5:S63-S67.
Lin JY, Li CS, Pan JT. Effects of various neuroactive substances on single-unit activities of hypothalamic arcuate neurons in brain slices. Brain Res Bull 1993;31:587-594.
Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009;296:E581-E591.
Aubry JM, Schwald M, Ballmann E, Karege F. Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation. Psychopharmacology (Berl) 2009;205:419-429.
Kang UG, Seo MS, Roh MS, Kim Y, Yoon SC, Kim YS. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett 2004;560:115-119.
Lu XH, Dwyer DS. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 2005;27:43-64.
Olianas MC, Dedoni S, Onali P. Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of ${\delta}$ -opioid receptor. Eur J Pharmacol 2011;660:341-350.
Roh MS, Seo MS, Kim Y, Kim SH, Jeon WJ, Ahn YM, et al. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 2007;39:353-360.
Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007;104:3456-3459.
Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 2010;31:484-497.
Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:945-954.
Murashita M, Kusumi I, Hosoda H, Kangawa K, Koyama T. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology 2007;32:777-784.
Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008;13:918-929.
Citrome L, Volavka J. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004;27:2087-2088; author reply 2089-2090.
Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004;71:195-212.
Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.